Skip to main content

Sirolimus-associated lymphoedema: eight new cases and a proposed mechanism

Buy Article:

$51.00 plus tax (Refund Policy)



Sirolimus, an inhibitor of the mammalian target of rapamycin (mTOR), is increasingly used as an agent for post-transplant immunosuppression and the treatment of solid organ and haematological malignancies and hamartomas. Its advantages include a lack of nephrotoxicity and a lower incidence of nonmelanoma skin cancers; adverse effects include delayed wound healing, increased lymphocoele formation and rarely lymphoedema. We report a series of eight cases of severe, sustained, unilateral and bilateral lymphoedema in patients receiving sirolimus for post-transplant immunosuppression, classify their lymphoscintigraphy findings and propose a mechanism of aetiology based on the interaction of mTOR with key mediators of lymphangiogenesis.

Keywords: lymphoedema; mammalian target of rapamycin inhibitor; rapamycin; sirolimus; vascular endothelial growth factor C; vascular endothelial growth factor receptor 3

Document Type: Case Report


Affiliations: Radiology, St George’s Hospital, Tooting, London SW17 0QT, U.K.

Publication date: 2009-06-01

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more